Q BioMed Inc. (QBIO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 3.43 Million USD | -53.16% |
| 2021 | 7.33 Million USD | -42.9% |
| 2020 | 12.84 Million USD | 60.22% |
| 2019 | 8.01 Million USD | -11.08% |
| 2018 | 9.01 Million USD | -27.09% |
| 2017 | 12.37 Million USD | 94.94% |
| 2016 | 6.34 Million USD | 566.55% |
| 2015 | 952.13 Thousand USD | 2402.33% |
| 2014 | 38.05 Thousand USD | 7510.0% |
| 2013 | 500.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | -100.0% |
| 2023 Q1 | 442.5 Thousand USD | -11.13% |
| 2022 Q1 | 1.16 Million USD | -28.98% |
| 2022 Q3 | 740.91 Thousand USD | -28.22% |
| 2022 Q4 | 497.92 Thousand USD | -32.8% |
| 2022 FY | 3.43 Million USD | -53.16% |
| 2022 Q2 | 1.03 Million USD | -11.44% |
| 2021 Q3 | 1.57 Million USD | -13.12% |
| 2021 Q1 | 2.31 Million USD | -29.82% |
| 2021 Q4 | 1.64 Million USD | 4.27% |
| 2021 Q2 | 1.81 Million USD | -21.6% |
| 2021 FY | 7.33 Million USD | -42.9% |
| 2020 FY | 12.84 Million USD | 60.22% |
| 2020 Q4 | 3.29 Million USD | 56.4% |
| 2020 Q1 | 5.83 Million USD | 200.6% |
| 2020 Q2 | 1.61 Million USD | -72.25% |
| 2020 Q3 | 2.1 Million USD | 30.07% |
| 2019 Q2 | 2.26 Million USD | 10.2% |
| 2019 Q1 | 2.05 Million USD | 11.38% |
| 2019 FY | 8.01 Million USD | -11.08% |
| 2019 Q4 | 1.94 Million USD | 10.56% |
| 2019 Q3 | 1.75 Million USD | -22.59% |
| 2018 Q3 | 2.98 Million USD | 48.33% |
| 2018 Q4 | 1.84 Million USD | -38.13% |
| 2018 FY | 9.01 Million USD | -27.09% |
| 2018 Q1 | 2.17 Million USD | -45.0% |
| 2018 Q2 | 2.01 Million USD | -7.42% |
| 2017 Q4 | 3.95 Million USD | 5.81% |
| 2017 FY | 12.37 Million USD | 94.94% |
| 2017 Q3 | 3.73 Million USD | 38.86% |
| 2017 Q2 | 2.69 Million USD | 35.03% |
| 2017 Q1 | 1.99 Million USD | -2.57% |
| 2016 Q2 | 776.04 Thousand USD | -59.81% |
| 2016 Q1 | 1.93 Million USD | 112.93% |
| 2016 FY | 6.34 Million USD | 566.55% |
| 2016 Q4 | 2.04 Million USD | 28.29% |
| 2016 Q3 | 1.59 Million USD | 105.42% |
| 2015 Q3 | 33.2 Thousand USD | 774.2% |
| 2015 Q2 | 3798.00 USD | -53.59% |
| 2015 Q1 | 8184.00 USD | -58.02% |
| 2015 FY | 952.13 Thousand USD | 2402.33% |
| 2015 Q4 | 906.95 Thousand USD | 2631.62% |
| 2014 FY | 38.05 Thousand USD | 7510.0% |
| 2014 Q4 | 19.49 Thousand USD | 218.62% |
| 2014 Q3 | 6118.00 USD | 33.9% |
| 2014 Q1 | 7869.00 USD | 0.0% |
| 2014 Q2 | 4569.00 USD | -41.94% |
| 2013 FY | 500.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -157.342% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 31.841% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 88.371% |
| Nascent Biotech, Inc. | 2.22 Million USD | -54.117% |
| Rebus Holdings, Inc. | 664 Thousand USD | -417.564% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 90.776% |
| Qrons Inc. | 643.67 Thousand USD | -433.906% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -782.168% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 94.017% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -727.148% |
| Skye Bioscience, Inc. | 13.54 Million USD | 74.633% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.04% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 30.12% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1213.063% |
| SQZ Biotechnologies Company | 85.61 Million USD | 95.986% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -17.845% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -128.819% |
| Mesoblast Limited | 5.9 Million USD | 41.772% |
| Marizyme, Inc. | 19.23 Million USD | 82.138% |
| Genus plc | 147.7 Million USD | 97.673% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 60.855% |
| Pharming Group N.V. | 225.49 Million USD | 98.476% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -67.746% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -156.169% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 58.788% |
| ContraFect Corporation | 56.88 Million USD | 93.959% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 22.048% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -132.401% |
| IMV Inc. | 37.7 Million USD | 90.887% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -23.161% |
| MultiCell Technologies, Inc. | 567.42 USD | -605558.595% |
| ONE Bio Corp. | 6.44 Million USD | 46.668% |
| Accustem Sciences Inc. | 3.74 Million USD | 8.269% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 96.001% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -546.029% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 86.095% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -30.794% |
| Biomind Labs Inc. | 994.18 Thousand USD | -245.674% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.54% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -95.299% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 48.845% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -84.332% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 13846.512% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 78.535% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -87.272% |
| GB Sciences, Inc. | 1.42 Million USD | -141.929% |
| Alpha Cognition Inc. | 9.7 Million USD | 64.591% |
| HST Global, Inc. | 140.9 Thousand USD | -2338.933% |
| CSL Limited | 3.44 Billion USD | 99.9% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -205.502% |
| Halberd Corporation | 74.84 Thousand USD | -4491.844% |
| Enzolytics Inc. | 2.17 Million USD | -57.679% |
| Agentix Corp. | 1.37 Million USD | -150.528% |
| Resverlogix Corp. | 12.71 Million USD | 72.965% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 5.864% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.776% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -229.179% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -42.899% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -117.597% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -0.929% |
| AVAX Technologies, Inc. | 7.31 Million USD | 52.989% |
| Zenith Capital Corp. | 8.94 Million USD | 61.572% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.584% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -19626.927% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -39.967% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1903.76% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -78.907% |
| Kadimastem Ltd | 2.41 Million USD | -42.592% |
| Helix BioMedix, Inc. | 1.97 Million USD | -74.268% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 68.376% |
| BioStem Technologies, Inc. | 22.97 Million USD | 85.042% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1793.615% |
| LadRx Corporation | 3.81 Million USD | 9.842% |
| Cell Source, Inc. | 4.32 Million USD | 20.547% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -272.127% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -272.127% |
| NovAccess Global Inc. | 2.46 Million USD | -39.317% |
| Affymax, Inc. | 39.38 Million USD | 91.274% |
| Itoco Inc. | 919.14 Thousand USD | -273.895% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 18.917% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -207.116% |
| Mobile Lads Corp. | 554.54 Thousand USD | -519.719% |
| CytoDyn Inc. | 18.05 Million USD | 80.969% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -13554.21% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1461.55% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -142.052% |
| SYBLEU INC | 160.87 Thousand USD | -2036.197% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -89.208% |
| International Stem Cell Corporation | 5.27 Million USD | 34.801% |
| Bioxytran, Inc. | 3.82 Million USD | 10.039% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -6428.301% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -16793.418% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 90.524% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -112.4% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -367.038% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -10.467% |
| Neutra Corp. | 243.82 Thousand USD | -1309.488% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 80.314% |
| PureTech Health plc | 144.59 Million USD | 97.623% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 83.228% |
| IXICO plc | 4.7 Million USD | 26.989% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 60.934% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.081% |
| CSL Limited | 3.89 Billion USD | 99.912% |
| Cellectis S.A. | 97.32 Million USD | 96.469% |